Table 2 Partial prophylaxis rates among ethnic/racial minorities
Dosing characteristics | Caucasian reference group (N= 3312) | African American (N= 2554) | Hispanic (N= 959) |
|---|---|---|---|
Total population | |||
Partial prophylaxis, % | 61.3 | 68.9 (p< 0.001) | 75.5 (p< 0.001) |
Mean (SD) doses among partially prophylaxed | 3.9 (1.8) | 3.8 (1.8) (p= 0.008) | 3.5 (1.7) (p< 0.001) |
Mean days between doses among gap >35 days | 50.3 (19.5) | 51.8 (19.2) (p= 0.063) | 54.6 (20.2) (p< 0.001) |
First palivizumab dose after November 30, % | 31.8 | 28.0 (p= 0.869) | 50.8 (p< 0.001) |
Infants with capitated coverage | |||
Number of infants | 787 | 863 | 190 |
Partial prophylaxis in capitated plans, % | 71.4 | 80.2 (p< 0.001) | 74.7 (p= 0.359) |
Mean (SD) doses among noncompliant | 3.8 (1.7) | 3.6 (1.6) (p= 0.194) | 3.2 (1.8) (p< 0.0001) |
Mean days between doses among gap >35 days | 50.5 (18.6) | 52.9 (20.9) (p= 0.094) | 55.0 (16.7) (p= 0.074) |
First palivizumab dose after November 30, % | 35.4 | 34.0 (p= 0.370) | 57.0 (p< 0.001) |
Infants with non-capitated coverage | |||
Number of infants | 2525 | 1691 | 769 |
Partial prophylaxis in capitated plans, % | 58.1 | 63.1 (p= 0.001) | 75.7 (p< 0.001) |
Mean (SD) doses among noncompliant | 4.0 (1.9) | 3.8 (1.9) (p= 0.073) | 3.6 (1.7) (p< 0.001) |
Mean days between doses among gap >35 days | 50.1 (19.8) | 51.0 (18.0) (p= 0.353) | 54.6 (20.9) (p= 0.001) |
First palivizumab dose after November 30, % | 30.4 | 24.2 (p= 0.040) | 49.3 (p< 0.001) |